Tandem transplants in the treatment of multiple myeloma. Pro.
Fassas
Athanasios B-T
AB
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. fassasathanasios@uams.edu
Tricot
Guido
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D012074:Remission Induction; D012086:Reoperation; D015996:Survival Rate; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide; D008558:Melphalan; D011241:Prednisone